MétaCan
Menu
Back to cohort
Record W4416797955 · doi:10.1007/s10875-025-01966-z

IgA and IgM-enriched Immunoglobulins in Primary Immunodeficiencies: a Pilot Study

2025· article· en· W4416797955 on OpenAlexaff
A Collet, Benjamin Coiffard, Emmanuel Ledoult, Claire Fieschi, Morgane Cheminant, Alexandra Serris, Felipe Suarez, Sébastien Sanges, Antoine Neel, R. Nové-Josserand, Sarah Stabler, Kinan El Husseini, Alice Huault, Pierre Cougoul, C. Mausservey, Nadim Cassir, Floriane Mirgot, Bertrand Meresse, Arnaud Dendooven, Sandrine Poizot, Tanguy Le Scornet, Anne-Sophie Bravard, Anne Conrad, Manon Levêque, Jehane Fadlallah, Cléa Melenotte, Claire Tinévez, Wadih Abou Chahla, Sylvain Dubucquoi, Myriam Labalette, Marion Malphettes, N. Schleinitz, Lionel Galicier, Jean‐François Viallard, Guy Gorochov, Guillaume Lefèvre

Bibliographic record

VenueJournal of Clinical Immunology · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmunodeficiency and Autoimmune Disorders
Canadian institutionsHotel Dieu Hospital
FundersSorbonne UniversitéGrifolsAgence Nationale de Sécurité du Médicament et des Produits de SantéFondation pour la Recherche MédicaleInstitut National de la Santé et de la Recherche MédicaleAgence Nationale de la RechercheEuropean CommissionBioCrystSwedish Orphan BiovitrumCSL Behring
KeywordsMedical microbiologyAntibodyPrimary immunodeficiencyImmunoglobulin ARespiratory systemImmunoglobulin GAntibody responseSecretory IgA

Abstract

fetched live from OpenAlex

Despite well-conducted replacement therapy with polyvalent immunoglobulins (IgRT), some patients with primary immunodeficiencies (PID) continue to experience recurrent or chronic infections. IgA and IgM, essential for mucosal and complement-mediated immunity, are absent or minimal in standard immunoglobulin products. The aim of this study is to evaluate the safety and clinical evolution profiles in PID patients with undetectable IgA/IgM levels and persistent infections despite standard IgRT, after introduction of an IgA- and IgM-enriched immunoglobulin preparation (IgGAM, Pentaglobin ® ). A compassionate use program (CUP) in France enrolled 20 PID patients with undetectable IgA/IgM levels, receiving IgGAM IV infusions every 7–14 days. Tolerance, infection frequency, hospitalizations, and biological markers (Ig levels, complement activation, salivary IgA) were analyzed prospectively. Twenty patients were included in the CUP at the time of analysis. No severe adverse event was reported. Half of the patients experienced mild to moderate hypersensitivity symptoms. Mean antibiotic courses dropped from 5.4 to 2.3/year ( p = 0.0009) and mean number of hospitalizations decreased from 2.6 to 1.2/year ( p = 0.01). Median serum IgA and IgM levels increased three months after IgGAM start. IgM and low levels of IgA were detected in saliva samples, suggesting at least a transient transfer of IgA/IgM from IgGAM into mucosal fluids. In patients with severe PID and undetectable IgA/IgM, IgGAM was associated with reduced infections and hospitalizations. Controlled studies are needed to confirm the benefit of IgA/M enriched immunoglobulin preparations in PID patients with persistent and/or recurrent respiratory or digestive infections.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.033
GPT teacher head0.341
Teacher spread0.308 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical ImmunologySame topicImmunodeficiency and Autoimmune DisordersFrench-language works237,207